We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00321321
First Posted: May 3, 2006
Last Update Posted: July 16, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Gentofte, Copenhagen
Results First Submitted: September 29, 2008  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Diagnostic
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Sulfonylurea

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
May 2006 - March 2007, Outpatient clinic and advertisement

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sulfonylurea No text entered.

Participant Flow:   Overall Study
    Sulfonylurea
STARTED   12 
COMPLETED   12 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sulfonylurea No text entered.

Baseline Measures
   Sulfonylurea 
Overall Participants Analyzed 
[Units: Participants]
 12 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   11 
>=65 years   1 
Age 
[Units: Years]
Mean (Standard Deviation)
 55  (7.6) 
Gender 
[Units: Participants]
 
Female   4 
Male   8 
Region of Enrollment 
[Units: Participants]
 
Denmark   12 


  Outcome Measures

1.  Primary:   Insulin Secretion   [ Time Frame: 0 - 90 minutes ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats


  More Information